BioInformant

Your Global Leader in Stem Cell Market Research

Home » investment

Novo Nordisk Foundation Commits DKK 5.5 Billion to the BioInnovation Institute (BII) through 2035

By Leave a Comment

In a strategic move set to reshape the European biotech and science innovation landscape, the Novo Nordisk Foundation has pledged a long-term investment of up to DKK 5.5 billion (≈ €736 million) to the Copenhagen-based BioInnovation Institute (BII), extending support through 2035. This unprecedented investment will expand BII’s role in commercializing science, scaling startups, and building cross-sector bridges across Europe.

The commitment also signals a broader push to close Europe’s long-standing gap between world-class research and global commercial leadership in emerging technologies. [Read more…]

5 Cord Blood Investors Impacting the Global Marketplace

By Leave a Comment

Inspired by the acquisition of Cord Blood Registry by AMAG Pharmaceuticals for $700M in June of 2015, this post considers five cord blood investors that are impacting the global marketplace.  It includes traditional investments, acquisitions, and contributions from wealthy founders. If you are operating within the cord blood industry, you need to know these market investors. [Read more…]

Cesca Therapeutics Acquires $15M Strategic Investment From Chinese Cloning Giant, Boyalife Group

By Leave a Comment

Cesca TherapeuticsOn February 3, 2016, Cesca Therapeutics (NASDAQ:KOOL) released news that Boyalife Group was making a $15 million strategic investment in the company.

Stock priced jumped following the news, although it has since been volatile.

Located in Rancho Cordova, California, Cesca Therapeutics specializes in the research, development, and commercialization of autologous cell-based therapeutics for regenerative medicine applications. With the stem cell and cord blood marketplace, the company is best known for it automated blood and bone marrow processing systems, such as the AutoXpress® Platform (AXP®), the MarrowXpress® Platform, the BioArchive® System, and others.

On the other hand, Boyalife Group is best known for its cloning technologies, although it describes itself as involved with “stem cell technologies, regenerative medicine, genomics and cloning, cancer immune therapies, disease mechanistic studies and innovative drug discovery.”

As stated in the press release:

“Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that affiliates of Boyalife Group have agreed to invest $15.0 million in the Company (the “Boyalife Financing”), enabling the Company to repay currently outstanding senior secured convertible debentures and retire associated Series B Warrants. The investments will also provide additional working capital to fund the Company’s ongoing operations and strategic initiatives.”

Additionally, Dr. Xiaochun Xu, Chairman and CEO of Boyalife Group commented:

“This investment lays the foundation for what we see as a strong and continuing strategic alliance between our two companies. Beyond Cesca’s existing pipeline of autologous cell-based therapies, this partnership has the potential to enable access to a much broader scope of clinical applications as well as accelerate penetration of the 1.3 billion person market in China.”

To learn more, visit www.CescaTherapeutics.com.

About BioInformant

BioInformant is the only research firm to serve the stem cell sector since it emerged. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.

Click here to view our global strategic reports for the stem cell industry.

Shopping cart0
There are no products in the cart!
Continue shopping
0